Last edition
News about "Biopharmaceutical Innovation"
Travere Therapeutics Receives USPTO Patent Allowance for Filspari Use in IgA Nephropathy
Travere Therapeutics has secured a Notice of Allowance from the USPTO for a patent application covering specific methods of using Filspari (sparsentan) in the treatment of IgA nephropathy, strengthening its rare kidney disease portfolio.
Biopharmaceutical Innovation | 29/05/2026 | By News Bureau
Pharming Secures EU Approval for Joenja as First Targeted Treatment for Rare Immune Disorder APDS
Pharming Group has received European Commission approval for Joenja, expanding treatment access for patients with activated PI3K delta syndrome and strengthening therapeutic options for rare immune disorders.
Biopharmaceutical Innovation | 26/05/2026 | By News Bureau
Incyte and Genesis Molecular AI have expanded their strategic collaboration to deploy advanced molecular AI technologies and proprietary research data, aiming to accelerate drug discovery and develop next-generation therapies through AI-powered molecular design.
Biopharmaceutical Innovation | 22/05/2026 | By News Bureau | 201
Alebund Pharmaceuticals has completed patient enrollment in its global phase 3 RESPOND-2 study evaluating AP301, a next-generation phosphate binder for CKD patients on dialysis.
Biopharmaceutical Innovation | 07/05/2026 | By News Bureau | 109
GSK's Efimosfermin Secures FDA Breakthrough and EMA PRIME Status for MASH Treatment
The dual regulatory designations from US FDA and European Medicines Agency fast-track development of GSK’s investigational liver therapy for metabolic dysfunction-associated steatohepatitis.
Biopharmaceutical Innovation | 29/04/2026 | By News Bureau | 110
ImmunoForge Unveils LMT15 Platform to Transform CNS Drug Delivery
The clinical-stage biotech firm ImmunoForge is advancing its next-generation blood-brain barrier shuttle technology, combining enhanced brain permeability with long-acting formulations to accelerate therapies for CNS and rare diseases.
Biopharmaceutical Innovation | 24/04/2026 | By News Bureau
Abbisko's Irpagratinib Secures EMA Orphan Drug Tag for Liver Cancer
European regulator grants rare disease designation to FGFR4 inhibitor, boosting its clinical development and commercial prospects in hepatocellular carcinoma.
Biopharmaceutical Innovation | 01/04/2026 | By News Bureau
EU Grants Conditional Approval to Rezurock for Chronic GVHD Treatment
European Commission authorises belumosudil for patients aged 12 plus with limited treatment options, marking a significant advance in managing a life-threatening post-transplant condition.
Biopharmaceutical Innovation | 01/04/2026 | By News Bureau
Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.
Biopharmaceutical Innovation | 30/12/2025 | By News Bureau | 176
Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.
Biopharmaceutical Innovation | 22/12/2025 | By News Bureau | 258
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy